Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: Simulation and dose replacement recommendations for the clinician

Journal of Clinical Pharmacy and Therapeutics

Volumn 31, Issue 4, 2006, Pages 321-329

  Dutta, S ^a   Reed, R C ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Adherence; Compliance; Computer simulation; Divalproex delayed release; Pharmacokinetics; Valproate

Indexed keywords

ANTICONVULSIVE AGENT; LIVER ENZYME; VALPROATE SEMISODIUM; VALPROIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPUTER SIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RELEASE; ENTERIC COATED TABLET; EPILEPSY; HUMAN; MONOTHERAPY; PATIENT COMPLIANCE; RISK ASSESSMENT; STEADY STATE;

ADULT; ANTICONVULSANTS; COMPUTER SIMULATION; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; EPILEPSY; HALF-LIFE; HUMANS; TIME FACTORS; TREATMENT REFUSAL; VALPROIC ACID;

EID: 33745948331     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2006.00739.x     Document Type: Article

References (23)

1. Brodie MJ, French JA (2000) Management of epilepsy in adolescents and adults. Lancet, 356, 323-329.
2. Browne TR, Holmes GL (2001) Epilepsy. New England Journal of Medicine, 344, 1145-1151.
3. Bowden CL, Brugger AM, Swann AC et al. (1994) Efficacy of divalproex vs. lithium and placebo in the treatment of mania. The Depakote Mania Study Group. Journal of the American Medical Association, 271, 918-924.
4. Pope HG, McElroy SL, Keck PE et al. (1991) Valproate in the treatment of acute mania- a placebo-controlled study. Archives of General Psychiatry, 48, 62-68.
5. Mathew NT, Saper JR, Silberstein SD et al. (1995) Migraine prophylaxis with divalproex. Archives of Neurology, 52, 281-286.
6. Becker WJ (1999) Evidence based migraine prophylactic drug therapy. Canadian Journal of Neurological Sciences, 26, S27-S23.
7. Gugler R, von Unruh GE (1980) Clinical pharmacokinetics of valproic acid. Clinical Pharmacokinetics, 5, 67-83.
8. Zaccara G, Messori A, Moroni F (1988) Clinical pharmacokinetics of valproic acid. Clinical Pharmacokinetics, 15, 367-389.
9. Levy RH, Shen DD, Abbott FS et al. (2002) Chapter 84. Valproic acid. Chemistry, biotransformation, and pharmacokinetics. In: Levy RH, et al., eds. Antiepileptic drugs. New York: Raven Press, 780-800.
10. Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clinical Therapeutics, 23, 1296-1310.
11. Cramer JA, Mattson RH, Prevey ML et al. (1989) How often is medication taken as prescribed? A novel assessment technique. Journal of the American Medical Association, 261, 3273-3277.
12. Beydoun A, Sackellares JC, Shu V (1997) Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration-response design clinical trial. Neurology, 48, 182-188.
13. Allen MH, Hirschfeld RM, Wozniak PJ et al. (2006) Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. American Journal of Psychiatry, 163, 1-4.
14. Keck PE, Bowden CL, Meinhold JM et al. (2005) Relationship between serum valproate and lithium levels and efficacy and tolerability in bipolar maintenance therapy. International Journal of Psychiatry in Clinical Practice, 9, 271-277.
15. D'Argenio DZ, Schumitzky A (1979) A program package for simulation and parameter estimation in pharmacokinetic symptoms. Computer Programs in Biomedicine, 9, 115-134.
16. Dutta S, Cloyd JC, Granneman GR et al. (2003) Oral/intravenous maintenance dosing of valproate following intravenous loading: a simulation. Epilepsy Research, 53, 29-38.
17. Cloyd JC, Dutta S, Cao G et al. (2003) Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy. Epilepsy Research, 53, 19-27.
18. Cramer JA, Glassman M, Rienzi V (2002) The relationship between poor medication compliance and seizures. Epilepsy and Behavior, 3, 339-342.
19. Keck PE, McElroy SL, Strakowski SM et al. (1996) Factors associated with pharmacologic noncompliance in patients with mania. Journal of Clinical Psychiatry, 57, 292-297.
20. Dutta S, Reed RC (2006) Distinct absorption characteristics of five oral formulations of valproic acid. Clinical Pharmacology and Therapeutics, 79, P74.
21. Cloyd JC, Fischer JH, Kriel RL et al. (1993) Valproic acid pharmacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. Clinical Pharmacology and Therapeutics, 53, 22-29.
22. Bourdet SV, Gidal BE, Alldredge BK (2001) Pharmacological management of epilepsy in the elderly. Journal of the American Pharmacists Association, 41, 421-436.
23. Felix S, Sproule BA, Hardy BG et al. (2003) Dose-related pharmacokinetics and pharmacodynamics of valproate in the elderly. Journal of Clinical Psychopharmacology, 23, 471-478.